Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cow's milk allergen, administered in the form of skimmed milk powder, is a biologic agent used in allergen immunotherapy (AIT) for the treatment of cow's milk allergy. The therapy involves the gradual administration of increasing doses of milk proteins—primarily caseins and whey proteins such as alpha-lactalbumin and beta-lactoglobulin—to induce immunological desensitization and clinical tolerance. The mechanism of action is characterized by a shift in the immune response from an IgE-mediated Th2 allergic profile toward a regulatory T-cell (Treg) and Th1-mediated response. This modulation leads to the production of allergen-specific IgG4 antibodies and a reduction in mast cell and basophil reactivity upon allergen exposure. In clinical research, such as the jRCT1031240155 trial in Japan, skimmed milk powder is being evaluated in combined oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) protocols to improve safety and efficacy outcomes in allergic patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cow's milk allergen.